Current Oncology Reports

, Volume 9, Issue 1, pp 55–59 | Cite as

Statistical issues in clinical trial design



This paper reviews some of the more salient recent developments in statistical aspects of clinical trial design methodology and suggests that more emphasis be placed on rigorous assessments of the new methodologies to place them in the context of existing methods, demonstrate their claimed advantages, and fully disclose their remaining limitations.


These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Rosenberger WF, Haines LM:Competing designs for phase I clinical trials: a review.Stat Med 2002,21:2757–2770.PubMedCrossRefGoogle Scholar
  2. 2.
    Gehan EA:The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent.J Chron Dis 1961,13:346–353.PubMedCrossRefGoogle Scholar
  3. 3.
    Simon R:Optimal two-stage design for phase II clinical trials.Control Clin Trials 1989,10:1–10.PubMedCrossRefGoogle Scholar
  4. 4.
    Estey E, Thall P:New designs for phase 2 clinical trials.Blood 2003,102:442–448.PubMedCrossRefGoogle Scholar
  5. 5.
    Schlesselman JJ, Reis IM:Phase II clinical trials in oncology: strengths and limitations of two-stage designs.Cancer Invest 2006,24:404–412.PubMedCrossRefGoogle Scholar
  6. 6.
    Bryant J, Day R:Incorporating toxicity considerations into the design of two-stage phase II clinical trials.Biometrics 1995,51:1372–1383.PubMedCrossRefGoogle Scholar
  7. 7.
    Thall PF, Cook JD:Dose-finding based on efficacy-toxicity trade-offs.Biometrics 2004,60:684–693.PubMedCrossRefGoogle Scholar
  8. 8.
    Thall PF, Simon R:Practical guidelines for phase IIB clinical trials.Biometrics 1994,50:337–349.PubMedCrossRefGoogle Scholar
  9. 9.
    Berry DA:A guide to drug discovery: Bayesian clinical trials.Nat Rev Drug Discov 2006,5:27–36.PubMedCrossRefGoogle Scholar
  10. 10.
    Thall PF, Wooten LH, Tannir NM:Monitoring event times in early phase clinical trials: some practical issues.Clin Trials 2005,2:467–78.PubMedCrossRefGoogle Scholar
  11. 11.
    Thall PF, Simon RM, Estey EH:Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.Stat Med 1995,14:357–79.PubMedCrossRefGoogle Scholar
  12. 12.
    Thall PF, Wathen JK, Bekele BN, et al.:Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.Stat Med 2003,22:763–780.PubMedCrossRefGoogle Scholar
  13. 13.
    Johnson JR, Williams G, Pazdur R:End points and United States Food and Drug Administration approval of oncology drugs.J Clin Oncol 2003,21:1404–1411.PubMedCrossRefGoogle Scholar
  14. 14.
    Temple R:FDA perspective on trials with interim efficacy evaluations.Stat Med 2006,25:3245–3249; discussion 3326–3347.PubMedCrossRefGoogle Scholar
  15. 15.
    Mehta T, Tanik M, Allison DB:Towards sound epistemological foundations of statistical methods for high-dimensional biology.Nat Genet 2004,36:943–947.PubMedCrossRefGoogle Scholar
  16. 16.
    Cook J:Collection of software to design, assess, and conduct Bayesian clinical trials. Accessed 7/3006.Google Scholar

Copyright information

© Current Science Inc. 2007

Authors and Affiliations

  1. 1.Department of Biostatistics and Applied MathematicsThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations